APS : Tuesday, 24 January 2017
ALGIERS- The group Saidal signed Tuesday, in Algiers, a partnership agreement with the Jordanian company Acdima to carry out bio-equivalence studies in Algeria.
Signed by Saidal’s CEO Yacine Tounsi and Acdima’s Director General Mohamed Khalifa, this agreement consists in the creation of a joint venture between the two parties which will be in charge of carrying out compliance studies of generic drugs with the original ones, and thus, in the new bio-equivalence centre of Saidal group located in Hussein Dey (Algiers).
This Algerian-Jordanian partnership provides, according to Tounsi, for a series of training sessions for Saidal’s executives in Algeria and Jordan before the launch of bio-equivalence studies of the products made by this public pharmaceutical group and other national private pharmaceutical industrial operators.
This joint-venture, in which Saidal will hold 60% and Acdima 40%, will be company “squarely independent” from Saidal for transparency reasons, said Tounsi.
The partnership in this project also relates to in-house training of technicians of Saidal that will begin in the next weeks in Jordan then Algeria to introduce them to bioequivalence studies, so far not available in Algeria, said the same official.
Up to now, generic manufacturers in Algeria buy their pharmaceutical records in order to use them in the domestic production of these drugs.
Regulations are evolving in Algeria, they will require drug manufacturers to conduct bioequivalence studies, so far not available in our country, he added.
Saidal’s bio-equivalence centre, erected in a support sructure, was inaugurated in January 2016.
